GlassScriptPhysician profile
Joseph D Hakes
NPI 1407000714
$3,165.83
in general payments reported to CMS, 2019-2025
24 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $503 · 2021: $613 · 2022: $376 · 2023: $539 · 2024: $487 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.20 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $388.34 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $374.75 | 2019-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $311.23 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $228.97 | 2020-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $221.29 | 2021-2025 | |
| Pfizer INC. | $177.05 | 2019-2025 | |
| Novo Nordisk INC | $141.42 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $118.29 | 2020-2024 | Shingrix, Bexsero, Arexvy |
| Amarin Pharma, INC. | $114.77 | 2019-2021 | |
| Amgen INC. | $90.59 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $84.16 | 2020-2024 | Gardasil 9, Vaxelis, Capvaxive |
| Novartis Pharmaceuticals Corporation | $82.31 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.47 | 2022-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $53.19 | 2022-2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $46.56 | 2025 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $46.12 | 2021 | |
| Exact Sciences Corporation | $39.29 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $33.47 | 2023 | |
| Lundbeck LLC | $31.69 | 2021 | |
| Mylan Specialty L.P. | $25.81 | 2021 | |
| Allergan, INC. | $17.73 | 2021 | |
| Dexcom, INC. | $16.12 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $14.01 | 2024 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hakes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.